Nigeria Secures €10.2 Million EU Partnership to Boost Local Pharmaceutical Manufacturing
Key Insights
Nigeria, the European Union (search), and France have signed a strategic €10.2 million partnership agreement under the Global Gateway's MAV+ Initiative to advance pharmaceutical manufacturing capacity and strengthen local health systems over a 44-month period from 2025-2028.
The Qualimeds Nigeria project aims to expand local production of quality-assured medicines, improve access to essential health technologies, and reinforce NIPRD (search) as a regional reference centre for bioequivalence, stability studies, and quality control.
German pharmaceutical giant Bayer has partnered with Nigeria's ChroMedix (search) to establish a reproductive health products (search) manufacturing facility in Anambra State as part of broader healthcare distribution and supply strengthening initiatives.
The Federal Government of Nigeria has secured a landmark €10.2 million partnership with the European Union (search) and France to dramatically expand the country's pharmaceutical manufacturing capabilities, marking a significant step toward healthcare self-sufficiency in Africa's most populous nation.
The strategic partnership agreement, signed under the Global Gateway's Manufacturing and Access to Vaccines, Medicines and Health Technologies (MAV+) Initiative, includes €10 million from the EU and €200,000 co-financing from the French Ministry for Europe and Foreign Affairs. The 44-month project, running from 2025-2028, will be implemented in collaboration with the Federal Ministry of Health and Social Welfare and the National Institute for Pharmaceutical Research and Development (NIPRD (search)).
Major Industry Partnership Anchors Initiative
The agreements were formalized during the Nigeria–EU Health Investment Forum in Abuja, themed "Made in Nigeria, Made for Health." A cornerstone of the initiative is a memorandum of understanding between German pharmaceutical giant Bayer and Nigeria's ChroMedix (search) to establish a reproductive health products (search) manufacturing facility in Anambra State.
Dr. Abdu Mukhtar, National Coordinator of the Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC (search)), stated that the partnerships would significantly enhance local production of healthcare products, tapping into a market currently valued at $46 billion.
Qualimeds Nigeria Project Framework
The project, named Quality Uplift for Advancing Local Industry in Medicine Standards (Qualimeds Nigeria), aims to bolster Nigeria's pharmaceutical ecosystem by expanding the local production of quality-assured medicines, improving access to essential health technologies, and promoting research-based innovation.
The initiative is expected to reinforce NIPRD (search) as a regional reference centre for critical activities such as bioequivalence, stability studies, and quality control, fostering regional collaboration with Rwanda and Senegal.
Dr. Obi Adigwe, Director-General/CEO of NIPRD (search), highlighted the significance of strategic partnerships in advancing Nigeria's pharmaceutical manufacturing. "We want to ensure that our people not only get the highest level of access to healthcare, but also catalyse socioeconomic development, job creation, capacity building, technology transfer, and revenue generation," he said.
International Commitment and Vision
EU Ambassador to Nigeria and ECOWAS, Gautier Mignot, emphasized the importance of this collaboration, describing it as proof of the enduring partnership between the EU, France, and Nigerian and West African stakeholders. "Let's combine the strength of our EU-Nigeria official partnership, EU-ECOWAS official partnership, with the dynamism of our companies on both sides to achieve a common goal: making Nigeria healthcare life-saving and sustainable, diversified, accessible, and affordable for all Nigerians, creating jobs and opportunities," Mignot stated.
France's Ambassador to Nigeria, Marc Fonbaustier, underscored France's commitment through the Global Health Strategy, noting that the principles guiding this strategy are equity, solidarity, and human dignity. "I am very proud that France, through the French Development Agency (search), is truly contributing to the implementation of the Qualimeds Nigeria project, as part of the Team Europe initiative. It truly reflects our shared values and collective commitment to strengthening health systems, advancing equity, and empowering communities through improved access to essential products and services," he said.
Expected Outcomes and Impact
Through laboratory modernization, technology transfer, and workforce training, the project is expected to boost Nigeria's self-sufficiency in medicines and vaccines, enhance regulatory compliance, and promote gender equity in biomanufacturing and research.
Expected outcomes include upgraded NIPRD (search) laboratories meeting international standards, increased Good Manufacturing Practice (GMP) compliance, stronger clinical research networks, and better integration of Nigeria's pharmaceutical sector into global innovation and production systems.
Dr. Mukhtar emphasized PVAC (search)'s efforts to position healthcare as a driver of economic growth and industrialization. "Today, we are signing new commitments, including those under the MAV+ initiative, to expand vaccine and health product manufacturing. The end goal is that every Nigerian, regardless of status or location, can access affordable, quality healthcare," he said.
The partnership reaffirms the joint commitment of the EU and France to improving health security, supporting local manufacturing, and driving sustainable growth within Nigeria's health sector, demonstrating dedication to building a resilient and prosperous health sector in Nigeria and the wider region.